Anastrozole
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Anastrozole and local guidelines before prescribing.
Mechanism
Non-steroidal aromatase inhibitor lowering oestrogen synthesis.
Uses
Hormone receptor-positive breast cancer in postmenopausal women.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Hot flushes, arthralgia, bone loss, vaginal dryness, fatigue.
Interactions
Do not combine with tamoxifen or oestrogens.
Contraindications and cautions
Premenopausal women; caution in osteoporosis
Monitoring
Bone density, lipids
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Caution in severe renal impairment
Overdose and reversal
Supportive
Special advice
Baseline bone density and vitamin D/calcium advice; not for premenopausal women unless ovarian suppression.
More from the textbook: uses, cautions and other points
- Chemoprevention (tamoxifen or anastrozole for women at moderate or high breast cancer risk; aspirin in Lynch syndrome).
Oncology: Principles - Anastrozole / letrozole | Joint pain, osteoporosis (DEXA, bisphosphonate).
Oncology: Principles - Anastrozole / letrozole | Postmenopausal ER-positive breast cancer; joint pain, bone loss; also prevention in high-risk women.
Oncology: Breast and Gynae Cancers - Options for high-risk women - earlier and more frequent screening (annual MRI from 30 for BRCA carriers, with mammography from 40), chemoprevention (tamoxifen or raloxifene before menopause/after; anastrozole after menopause), risk-reducing mastectomy (reduces risk by about 90% or more) and risk-reducing salpingo-oophorectomy.
Surgey: Breast and endocrine surgery - Risk management for moderate or high risk without a known variant - enhanced mammographic surveillance from 40 (annual), MRI in selected high-risk women, chemoprevention - tamoxifen (premenopausal) or anastrozole (postmenopausal) for 5 years.
Clinical Genetics: Cancer genetics and inherited cardiovascular conditions
Where it is discussed in the book
- Oncology: Principles (2 mentions)
- Oncology: Breast and Gynae Cancers (1 mention)
- Surgey: Breast and endocrine surgery (1 mention)
- Clinical Genetics: Cancer genetics and inherited cardiovascular conditions (1 mention)